On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

552c7ae14Space

Health

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

1 debate·6,984 claims·43 news stories

0